Relationship between levodopa concentration, dyskinesias, and motor effect in Parkinsonian patients: A 3-year follow-up study

Clinical Neuropharmacology

Volumn 20, Issue 5, 1997, Pages 409-418

  Contin, Manuela ^a   Riva, Roberto ^a   Martinelli, Paolo ^a   Albani, Fiorenzo ^a   Baruzzi, Agostino ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Dynamic modeling; Dyskinesias; Kinetic; Levodopa; Motor tests; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; LEVODOPA;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DYSKINESIA; FEMALE; FOLLOW UP; HUMAN; MALE; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030759962     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199710000-00005     Document Type: Article

References (28)

1. Marsden CD. Parkinson's disease. J. Neurol Neurosurg Psychiatry 1994;57:672-81.
2. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Pharmacodynamic modeling or oral levodopa: clinical application in Parkinson's disease. Neurology 1993;43:367-71.
3. Harder S, Baas H, Rietbrock S. Concentration-effect relationship of levodopa in patients with Parkinson's disease. Clin Pharmocokinet 1995;29:243-56.
4. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order. Ann Neurol 1996;39:561-73.
5. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: Central pathophysiologic mechanisms, Part II. Ann Neurol 1988;24:372-8.
6. Mouradian MM, Heuser IJE, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskineasis in Parkinson's disease. Ann Neurol 1989;25:523-6.
7. Nutt JG, Woodward WR, Carter JH, Gancher ST. Effect of long-term therapy on the pharmacodynamics of levodopa: relation to on-off phenomenon. Arch Neurol 1992;49:1123-30.
8. Gibb WRG, Lees AJ. The relevance of the Lewy body of pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-52.
9. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-45.
10. Contin M, Riva R, Martinelli P, et al. Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuations. Clin Neuropharmacol 1990;13:19-28.
11. Baruzzi A, Contin M, Albani F, Riva R. Simple and rapid micromethod for the determination ol levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 1986;375:165-9.
12. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter-and intrarater reliability assessment. Movement Disord 1994;9:390-4.
13. Gomeni C, Gomeni R. IGPHARM: interactive graphic package for pharmacokinetic analysis. Comput Biomed Res 1978;11:345-61.
14. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979;25-358-71.
15. Hughes AJ, Frankel JP, Kempster PA, et al. Motot response to levodopa in patients with Parkinsonian motor fluctuations: a follow-up study over three years. J Neurol Neurosurg Psychiatry 1994;57:430-4.
16. Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson's disease. Neurology 1994;44;1287-92.
17. Nelson MV, Berchou RC, Lewitt PA, et al. Pharmacokinetic and pharmacodynamic modeling of L-Dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet. Clin Neuropharmacol 1989;12:91-7.
18. Contin M, Riva R, Albani F, Baruzzi A. Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clin Pharmacokinet 1996;6:463-81.
19. Melamed E. Interaction of exogenous L-Dopa with nigrostriatal dopaminergic neurons in Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, eds. Parkinson's disease: Anatomy, pathology and therapy. New York: Raven Press, 1990:61-6. (Advances in Neurology: vol. 53).
20. Melamed E. Interaction of exogenous L-Dopa with nigrostriatal dopaminergic neurons in Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, eds. Parkinson's disease: Anatomy, pathology and therapy. New York: Raven Press, 1990:61-6. (Advances in Neurology: vol. 53).
21. Watchel SR, Abercrombie ED. L-3,4-Dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: Differential effects of monoamine oxidase A and B inhibitor.J Neurochem 1994;63:108-17.
22. Crossman AR. A hypothesis on the pathophysiologic mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment. Movement Disord 1990;5:100-8.
23. Blanchet PJ, Gomez-Mancilla B, Di Paolo T, Bedard PJ. Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia? Fund Clin Pharmacol 1995;9:1-9.
24. Calne DB. Initiating treatment for idiopathic parkinsonism. Neurology 1994;44(Suppl 6)19-22.
25. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. Eur Neurol 1997;37:23-7.
26. Brannan T, Martinez-Tica J, Di Rocco A, Yahr MD. Low and high dose bromocriptine have different effects on striatal dopamine release: an in vivo study. J Neurol Transm 1993;6:81-7.
27. Przedborski S, Levivier M, Raftopoulos C, Naini AB, Hildebrand J. Peripheral and central pharmacokinetics of apomorphine and its effect on dopamine metabolism in humans. Movement Disorder 1995;10:28-36.
28. Dethy S, Laute MA, Luxen A, Hildebrand J, Goldman S. Effect of pergolide on endogenous and exogenous L-Dopa metabolism in the rat striaturn: a microdialysis study. J Neurol Transm 1995;101:1-11.